Highest development stage: Preclinical

Development dropped

Gram-positive activity

Gram-negative activity

Mechanism of Action/Target pathogen: This was less active against MRSA and Pseudomonas than imipenem. Used against MRSA and CAP

Reason dropped: The dosage tested in phase I was suggested to be administered 3 or 4 times daily. This inconvenience could be the reason of discontinuation (1). It also had a very short half life (2) Additionally, this appeared to be less potent than ritipenem